Si-Bone ( (SIBN) ) has released its Q4 earnings. Here is a breakdown of the information Si-Bone presented to its investors.
SI-BONE, Inc. is a medical device company specializing in the development of innovative technologies for the surgical treatment of sacropelvic disorders, primarily operating within the healthcare sector. Known for pioneering minimally invasive SI joint surgery, SI-BONE has established itself as a leader in its field.
In its latest earnings report, SI-BONE, Inc. announced record financial results for the fourth quarter of 2024, highlighting a significant 26% increase in worldwide revenue and achieving positive adjusted EBITDA. The company also provided guidance for 2025, projecting continued growth and financial improvement.
Key financial metrics from the fourth quarter of 2024 include a worldwide revenue of $49.0 million, a 26% increase from the previous year, and a U.S. revenue increase of 28%. The company reported a gross margin of approximately 79% and a net loss reduction of 59% to $4.5 million. Notably, SI-BONE achieved a positive adjusted EBITDA of $1.9 million, marking a substantial improvement from the previous year’s loss.
For the fiscal year 2024, SI-BONE reported a 20% increase in worldwide revenue to $167.2 million and a 21% increase in U.S. revenue. The company’s net loss improved by 29% to $30.9 million, and adjusted EBITDA showed a 71% improvement, reflecting the company’s strategic investments and operational efficiencies.
Looking ahead, SI-BONE anticipates continued revenue growth in 2025, with expectations of achieving positive adjusted EBITDA for the full year. The company remains focused on expanding platform adoption and improving margins, supported by favorable reimbursement dynamics and ongoing innovation in its product offerings.